Akebia Therapeutics/$AKBA
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About Akebia Therapeutics
Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics for people with kidney disease. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor approved in Japan for the treatment of anemia due to chronic kidney disease, in adult patients, HIF-PH inhibitors in preclinical development.
Ticker
$AKBA
Sector
Primary listing
Employees
181
Headquarters
Website
AKBA Metrics
BasicAdvanced
$541M
-
-$0.16
0.68
-
Price and volume
Market cap
$541M
Beta
0.68
52-week high
$4.08
52-week low
$1.52
Average daily volume
4.1M
Financial strength
Current ratio
1.977
Quick ratio
1.77
Long term debt to equity
609.431
Total debt to equity
670.329
Interest coverage (TTM)
0.14%
Profitability
EBITDA (TTM)
23.348
Gross margin (TTM)
83.23%
Net profit margin (TTM)
-17.91%
Operating margin (TTM)
1.96%
Revenue per employee (TTM)
$1,130,000
Management effectiveness
Return on assets (TTM)
0.89%
Return on equity (TTM)
1,610.77%
Valuation
Price to revenue (TTM)
2.321
Price to book
18.36
Price to tangible book (TTM)
-17.99
Price to free cash flow (TTM)
-185.404
Free cash flow yield (TTM)
-0.54%
Free cash flow per share (TTM)
-0.011
Growth
Revenue change (TTM)
16.75%
Earnings per share change (TTM)
-21.58%
3-year revenue growth (CAGR)
-11.55%
3-year earnings per share growth (CAGR)
-44.00%
10-year earnings per share growth (CAGR)
-21.86%
What the Analysts think about AKBA
Analyst ratings (Buy, Hold, Sell) for Akebia Therapeutics stock.
Bulls say / Bears say
Total Q2 2025 revenues climbed 43% year-over-year to $62.5 million, driven by $13.3 million in Vafseo sales and $47.2 million in Auryxia sales, marking the company’s strongest quarter ever (Akebia IR).
Vafseo secured commercial supply agreements covering almost all U.S. dialysis patients, began shipping January 9, 2025, and registered prescriptions from over 725 prescribers with an 80% refill rate in Q2, demonstrating strong initial uptake (Akebia IR).
Akebia ended Q1 2025 with $113.4 million in cash and cash equivalents, reinforced by a $50 million public offering, providing funding to support commercial expansion and pipeline trials through at least 2027 (Akebia IR).
Auryxia lost U.S. exclusivity on March 20, 2025, exposing its $47.2 million Q2 revenue stream to generic competition that could significantly reduce sales once generics are approved (Akebia IR).
Broad adoption of Vafseo depends on large dialysis providers implementing prescribing protocols—currently, only a pilot program with DaVita started in Q3—pushing meaningful revenue contributions to late 2025 (Akebia IR).
Key post-marketing data from VOICE will not be available until early 2027 and the VALOR trial for non-dialysis CKD patients is only set to begin mid-to-late 2025, delaying prospects for label expansion into a multi-billion dollar market (Akebia IR).
Data summarised monthly by Lightyear AI. Last updated on 8 Nov 2025.
AKBA Financial Performance
Revenues and expenses
AKBA Earnings Performance
Company profitability
AKBA News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Akebia Therapeutics stock?
Akebia Therapeutics (AKBA) has a market cap of $541M as of November 09, 2025.
What is the P/E ratio for Akebia Therapeutics stock?
The price to earnings (P/E) ratio for Akebia Therapeutics (AKBA) stock is 0 as of November 09, 2025.
Does Akebia Therapeutics stock pay dividends?
No, Akebia Therapeutics (AKBA) stock does not pay dividends to its shareholders as of November 09, 2025.
When is the next Akebia Therapeutics dividend payment date?
Akebia Therapeutics (AKBA) stock does not pay dividends to its shareholders.
What is the beta indicator for Akebia Therapeutics?
Akebia Therapeutics (AKBA) has a beta rating of 0.68. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.